The merger, 16 months in the planning process, has been called off in a mutual agreement between the two companies.
At the end of July 2023, multistate cannabis companies Cresco Labs and Columbia Care announced that there would be no $2 billion merger, which had been first announced in March of 2022 (1). The merger was originally predicted to be one of the largest in the industry (2). Finalizations of the agreement were delayed once in March 2023 and again in June 2023 before being called off completely (3).
“In light of the evolving landscape in the cannabis industry, we believe the decision to terminate the planned transaction is in the long-term interest of Cresco Labs and our shareholders,” Cresco Labs CEO Charles Bachtell said in a press release (1).
In November of 2022, the companies also announced that nine dispensaries and three production facilities in three different states would be sold to entrepreneur and hip-hop mogul Sean “Diddy” Combs in order to fulfill state requirements that certain assets must be sold before the merger could continue (4). That agreement, said to be worth $185 million, has also been terminated (1). It would have created “the first minority-owned and operated, vertically integrated multistate operator,” according to both companies (4).
Cresco Labs and Columbia Care published the same press release on their websites concerning the terminated merger (1). A press release from Columbia Care dated July 31, 2023, also explained the company’s recent accomplishments and plans to move forward (5).
“With the uncertainty of the past 16 months behind us, along with the enthusiasm and energy that accompanies moments of renewal, our team welcomes the next stage of Columbia Care’s growth and expansion,” Nicholas Vita, CEO of Columbia Care said in the press release (5). “In spite of the challenges we have faced, the team has remained committed to the success of our Company and, as is obvious from the pace of activity, has been engaged at all levels, actively preparing for the future.”
Columbia Care is based in New York and Cresco Labs is headquartered in Chicago (3).
References
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Khan
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Khan
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
German Medical Cannabis Market Has Yet to Reach Its Full Potential
December 25th 2024Germany’s Cannabis Act (CanG) is beginning to transform the country's medical cannabis market, with potential opportunities to expand telemedicine, improve physician training, and enhancing accessibility in this rapidly growing industry.